Synergy Pharmaceuticals Inc (SGYP) Given Average Recommendation of “Buy” by Analysts

Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) have been assigned a consensus recommendation of “Buy” from the nine analysts that are presently covering the stock. Two analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $12.21.

A number of research firms recently commented on SGYP. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Synergy Pharmaceuticals in a research note on Friday. Canaccord Genuity reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Synergy Pharmaceuticals in a research note on Friday. Oppenheimer Holdings Inc. set a $9.00 price objective on shares of Synergy Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 10th. Zacks Investment Research lowered shares of Synergy Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 3rd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Synergy Pharmaceuticals in a research note on Saturday, April 22nd.

WARNING: This piece was originally reported by Mideast Time and is owned by of Mideast Time. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.mideasttime.com/synergy-pharmaceuticals-inc-sgyp-given-average-recommendation-of-buy-by-analysts/1708297.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SGYP. Paulson & CO. Inc. acquired a new position in Synergy Pharmaceuticals during the fourth quarter worth $146,700,000. Orbimed Advisors LLC increased its position in Synergy Pharmaceuticals by 205.2% in the fourth quarter. Orbimed Advisors LLC now owns 18,241,398 shares of the biopharmaceutical company’s stock worth $111,090,000 after buying an additional 12,264,750 shares in the last quarter. Great Point Partners LLC acquired a new position in Synergy Pharmaceuticals during the third quarter worth $35,386,000. State Street Corp increased its position in Synergy Pharmaceuticals by 100.9% in the first quarter. State Street Corp now owns 12,626,115 shares of the biopharmaceutical company’s stock worth $58,841,000 after buying an additional 6,342,446 shares in the last quarter. Finally, TimesSquare Capital Management LLC acquired a new position in Synergy Pharmaceuticals during the first quarter worth $11,650,000. Institutional investors and hedge funds own 55.36% of the company’s stock.

Shares of Synergy Pharmaceuticals (NASDAQ:SGYP) traded down 1.75% on Friday, reaching $3.92. The company’s stock had a trading volume of 3,814,990 shares. Synergy Pharmaceuticals has a 1-year low of $3.15 and a 1-year high of $7.15. The stock’s market capitalization is $881.80 million. The stock has a 50-day moving average of $4.21 and a 200 day moving average of $5.23.

Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.07. The company had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.10 million. On average, equities analysts forecast that Synergy Pharmaceuticals will post ($0.91) EPS for the current year.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

5 Day Chart for NASDAQ:SGYP

Receive News & Ratings for Synergy Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.